ImaRx Pharma, DuPont Merck deal

DuPont Merck received exclusive rights in North America and Latin America to cardiology and radiology uses of MRX-115 Aerosomes, ImaRx's second-generation ultrasound contrast agent. ImaRx plans to start a Phase II trial of the product in cardiac and blood panel imaging in December. DuPont Merck will assume responsibility for clinical development of cardiology and radiology indications for MRX-115 upon completion of the trial. ...